RecruitingPhase 2NCT03919461

Colorectal Metastasis Prevention International Trial 2

Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival


Sponsor

Assaf-Harofeh Medical Center

Enrollment

200 participants

Start Date

Feb 28, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The short perioperative period (days to weeks around surgery) is characterized by stress-inflammatory responses, including catecholamines (CAs, e.g., adrenaline) and prostaglandins (PGs, e.g., prostaglandin-E2) release, and induce deleterious pro-metastatic effects. Animal studies implicated excess perioperative release of CAs and PGs in facilitating cancer progression by affecting the malignant tissue, its local environment, and anti-metastatic immune functions. Congruently, animal studies conducted by the investigators indicate that combined use of the beta-adrenergic blocker, propranolol, and the prostaglandins inhibitor, etodolac - but neither drug separately - efficiently prevented post-operative metastatic development. Two recently conducted clinical trials, conducted by the investigators, in three medical centers in Israel, recruiting breast (n=38) and colorectal (n=34) cancer patients, assessing the safety and short-term efficacy of perioperative propranolol and etodolac treatment. Drugs were well tolerated, without severe adverse events. Importantly, molecular/biological analyses of the excised primary tumor indicated that drug treatment caused promising anti-metastatic transformations, as well as improvements in immune and inflammatory indices. These included (i) decreased tumor cell capacity to migrate, (ii) reduced pro-metastatic capacity of the malignant tissue, and (iii) improvement in immune infiltrating into the tumor (Paper published in Clinical Cancer Research, 2017). Herein, the investigators propose to conduct a double-blind placebo-controlled two-arm Phase II clinical trial in 200 colorectal cancer patients undergoing curative surgery in Israel. A perioperative 20-day drug treatment will be initiated 5 days before surgery. Primary outcomes will include (i) 3-year disease-free-survival (DFS), and 5-year overall survival (OS); and (ii) biological markers in blood samples, and in the excised tumor tissue. Secondary outcomes will include safety indices and psychological measures of depression, anxiety, distress, and fatigue


Eligibility

Min Age: 20 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This international trial is testing whether a medication given during surgery to remove colon or rectal cancer can reduce the risk of cancer spreading to other organs (particularly the liver) after the operation. **You may be eligible if...** - You are between 20 and 80 years old - You are scheduled for surgery to remove colon or rectal cancer with the intent to cure - You have a single tumor confirmed by colonoscopy and biopsy, with no known spread to other organs - You are in good overall health (ECOG 0-1) **You may NOT be eligible if...** - You already have cancer that has spread (metastatic disease) - Your surgery is not planned with curative intent - You have kidney failure, active inflammatory bowel disease, or other conditions that interfere with eligibility Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPropranolol and etodolac

A perioperative combined drug regimen

OTHERPlacebo

Placebo


Locations(6)

HaEmek Medical Center

Afula, Israel

Rambam Health Care Campus

Haifa, Israel

Rabin Medical Center

Petah Tikva, Israel

Sourasky Medical Center

Tel Aviv, Israel

Sheba Medical Center

Tel Litwinsky, Israel

Asaf Harofeh Medical Center

Ẕerifin, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03919461


Related Trials